Autolus Therapeutics (AUTL) announces business updates and an overview of 2025 milestones. Ongoing commercial launch of AUCATZYL on track, with 24 treatment centers fully authorized as of January 10th; National Comprehensive Cancer Network adds AUCATZYL to its Clinical Practice Guidelines in Oncology; Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23rd R&D investor event. 2025 Events & Milestones: Obe-cel in autoimmune disease: initial data from SLE Phase 1 study Q1 2025; R&D Investor Event, New York City April 23, 2025; Initial data from PY01 trial of obe-cel in pediatric ALL H2 2025; MHRA & EMA approvals for obe-cel in ALL H2 2025; SLE Phase 1 trial presentation at medical conference H2 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL: